A Phase IV Open Label Study of the Effects of a Five Minute Infusion Time for Ethyol (Amifostine) in Patients Undergoing Chemotherapy

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically proven cancer No brain or other
CNS metastases (including prior treated metastases)

PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-1 Life Expectancy:
Not specified Hematopoietic: Not specified Hepatic: No grade 3 or greater hepatic
dysfunction Renal: No hypercalcemia Cardiovascular: No uncontrolled hypotension Other: Not
pregnant or nursing Effective contraceptive method must be used by fertile patients No
psychosis No severe concurrent illness other than neoplasia No epileptic seizures during
the previous year, migraines, gastrointestinal obstructions, or other causes of vomiting
No prior or concurrent amifostine contraindications No prior known contraindications or
sensitivity to dexamethasone, granisetron, ondansetron, prochlorperazine, diphenhydramine,
cimetidine, or magnesium

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
Endocrine therapy: No prior estrogen within 24 hours of amifostine therapy Radiotherapy:
Not specified Surgery: Not specified Other: No prior alcohol, disulphiram, tetracycline,
or erythromycin within 24 hours of amifostine therapy No prior antiemetics such as
benzodiazepines, antipsychotics, anticonvulsants, or antihistamines within 24 hours of
amifostine therapy